Patent SG-11201900394S-A (SG)
Title: Beta-lactamase inhibitors
Inventor: CASAREZ ANTHONY
IPC: C07D519/06
Filed: 2017-09-28
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property MD HIM 0 11101 010 11111 01 II 0 011101 100 11011101 OH I 11110 ill OEN Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\" WO 2018/060926 Al 05 April 2018 (05.04.2018) WIP0 I PCT (51) International Patent Classification: SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, C07D 519/06 (2006.01) A61P 31/04 (2006.01) TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. A61K 31/535 (2006.01) CO7D 471/18 (2006.01) (84) Designated States (unless otherwise indicated, for every (21) International Application Number: kind of regional protection available): ARIPO (BW, GH, PCT/IB2017/055973 GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (22) International Filing Date: UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, 28 September 2017 (28.09.2017) TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (25) Filing Language: English MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (26) Publication Language: English TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (30) Priority Data: 62/401,022 28 September 2016 (28.09.2016) US Declarations under Rule 4.17: — (71) Applicant: NOVARTIS AG [CH/CH]; Lichtstrasse 35, as to applicant's entitlement to apply for and be granted a patent (Rule 4.1700) 4056 Basel (CH). Published: (72) Inventors: CASAREZ, Anthony; Novartis Institutes for — with international search report (Art. 21(3)) BioMedical Research, Inc., 5300 Chiron Way, Emeryville, _ before the expiration of the time limit for amending the 94608 (US). FUREGATI, Markus; Novartis Pharma AG, claims and to be republished in the event of receipt of Postfach, 4002 Basel (CH). KOCH, Guido; Novartis Phar- amendments (Rule 48.2(h)) ma AG, Postfach, 4002 Basel (CH). LIN, Xiaodong; No- vartis Institutes for BioMedical Research, Inc., 5300 Ch- iron Way, Emeryville, California 94608 (US). OSSOLA, Flavio; Novartis Pharma AG, Postfach, 4002 Basel (CH). RECK, Folkert; Novartis Institutes for BioMedical Re- search, Inc., 5300 Chiron Way, Emeryville, California 94608 (US). SIMMONS, Robert Lowell; Novartis Insti- tutes for BioMedical Research, Inc., 5300 Chiron Way, Emeryville, California 94608 (US). ZHU, Qingming; No- vartis Institutes for BioMedical Research, Inc., 5300 Chiron Way, Emeryville, California 94608 (US). (74) Agent: NOVARTIS AG; Lichtstrasse 35, 4056 Basel (CH). = (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, ,tD N 01 0 ,tDo 0 --.... hi Il 0 0 N 1-1 (54) Title: BETA-LACTAMASE INHIBITORS (57) : This invention pertains generally to compounds of Formula (A), as further described herein, which act as beta-lactamase inhibitors, and salts, crystalline forms and formulations thereof. In certain aspects, the invention pertains to methods of using such compounds in combination with a beta-lactam antibiotic to treat infections caused by Gram-negative bacteria, including drug-resistant strains. \ os0 3 E1 (A) C